{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:15:48Z","timestamp":1783970148550,"version":"3.55.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011749","name":"Melvin and Bren Simon Cancer Center, Indiana University","doi-asserted-by":"publisher","award":["CA082709"],"award-info":[{"award-number":["CA082709"]}],"id":[{"id":"10.13039\/100011749","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"DOI":"10.1186\/s13073-025-01503-y","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T08:00:17Z","timestamp":1752566417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups"],"prefix":"10.1186","volume":"17","author":[{"given":"Enze","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumaima","family":"Jaouadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis S.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvathi","family":"Sudha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek S.","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Hamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"10","key":"1503_CR1","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","volume":"33","author":"AH Bazarbachi","year":"2019","unstructured":"Bazarbachi AH, Al Hamed R, Malard F, Harousseau JL, Mohty M. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019;33(10):2343\u201357.","journal-title":"Leukemia"},{"issue":"6","key":"1503_CR2","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8(6):e446\u201361.","journal-title":"Lancet Haematol"},{"issue":"2","key":"1503_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.hoc.2023.12.002","volume":"38","author":"N van de Donk","year":"2024","unstructured":"van de Donk N, Zweegman S. Monoclonal antibodies in the treatment of multiple myeloma. Hematol Oncol Clin North Am. 2024;38(2):337\u201360.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"1503_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ajh.26379","volume":"97","author":"A Lakshman","year":"2022","unstructured":"Lakshman A, Kumar SK. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update. Am J Hematol. 2022;97(1):99\u2013118.","journal-title":"Am J Hematol"},{"issue":"13","key":"1503_CR5","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.2023022499","volume":"143","author":"H Lee","year":"2024","unstructured":"Lee H, Neri P, Bahlis NJ. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms. Blood. 2024;143(13):1211\u20137.","journal-title":"Blood"},{"issue":"4","key":"1503_CR6","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Via","year":"2021","unstructured":"Da Via MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27(4):616\u20139.","journal-title":"Nat Med"},{"issue":"12","key":"1503_CR7","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282\u201395.","journal-title":"Cancer Discov"},{"issue":"16","key":"1503_CR8","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood.2021015161","volume":"139","author":"GSF Anderson","year":"2022","unstructured":"Anderson GSF, Ballester-Beltran J, Giotopoulos G, Guerrero JA, Surget S, Williamson JC, et al. Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. Blood. 2022;139(16):2471\u201382.","journal-title":"Blood"},{"issue":"7","key":"1503_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101110","volume":"4","author":"F Di Meo","year":"2023","unstructured":"Di Meo F, Iyer A, Akama K, Cheng R, Yu C, Cesarano A, et al. A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. Cell Rep Med. 2023;4(7): 101110.","journal-title":"Cell Rep Med"},{"issue":"6","key":"1503_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132(6):587\u201397.","journal-title":"Blood"},{"issue":"23","key":"1503_CR11","doi-asserted-by":"publisher","first-page":"6202","DOI":"10.1182\/blood-2010-06-292243","volume":"117","author":"P Neri","year":"2011","unstructured":"Neri P, Ren L, Azab AK, Brentnall M, Gratton K, Klimowicz AC, et al. Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood. 2011;117(23):6202\u201313.","journal-title":"Blood"},{"issue":"9","key":"1503_CR12","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024;56(9):1878\u201389.","journal-title":"Nat Genet"},{"issue":"8","key":"1503_CR13","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-22-1769","volume":"83","author":"L Yao","year":"2023","unstructured":"Yao L, Wang JT, Jayasinghe RG, O\u2019Neal J, Tsai CF, Rettig MP, et al. Single-cell discovery and multiomic characterization of therapeutic targets in multiple myeloma. Cancer Res. 2023;83(8):1214\u201333.","journal-title":"Cancer Res"},{"issue":"12","key":"1503_CR14","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1182\/blood-2018-02-832576","volume":"132","author":"PJ Teoh","year":"2018","unstructured":"Teoh PJ, An O, Chung TH, Chooi JY, Toh SHM, Fan S, et al. Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood. 2018;132(12):1304\u201317.","journal-title":"Blood"},{"issue":"1","key":"1503_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41467-019-08679-z","volume":"10","author":"X Agirre","year":"2019","unstructured":"Agirre X, Meydan C, Jiang Y, Garate L, Doane AS, Li Z, et al. Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response. Nat Commun. 2019;10(1):821.","journal-title":"Nat Commun"},{"issue":"1","key":"1503_CR16","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1038\/s41467-024-48327-9","volume":"15","author":"TS Johnson","year":"2024","unstructured":"Johnson TS, Sudha P, Liu E, Becker N, Robertson S, Blaney P, et al. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed\/refractory multiple myeloma. Nat Commun. 2024;15(1):4144.","journal-title":"Nat Commun"},{"issue":"1","key":"1503_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics"},{"issue":"4","key":"1503_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417\u20139.","journal-title":"Nat Methods"},{"issue":"3","key":"1503_CR19","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170(3):564-76 e16.","journal-title":"Cell."},{"issue":"10","key":"1503_CR20","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1182\/blood.2019000080","volume":"134","author":"U Munawar","year":"2019","unstructured":"Munawar U, Rasche L, Muller N, Vogt C, Da-Via M, Haertle L, et al. Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness. Blood. 2019;134(10):836\u201340.","journal-title":"Blood"},{"issue":"7","key":"1503_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7): e47.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"1503_CR22","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556\u201360.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"1503_CR23","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98\u2013102.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1503_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/bib\/bbz158","volume":"22","author":"L Geistlinger","year":"2021","unstructured":"Geistlinger L, Csaba G, Santarelli M, Ramos M, Schiffer L, Turaga N, et al. Toward a gold standard for benchmarking gene set enrichment analysis. Brief Bioinform. 2021;22(1):545\u201356.","journal-title":"Brief Bioinform"},{"issue":"12","key":"1503_CR25","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nbt1210-1248","volume":"28","author":"M Uhlen","year":"2010","unstructured":"Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010;28(12):1248\u201350.","journal-title":"Nat Biotechnol"},{"issue":"46","key":"1503_CR26","doi-asserted-by":"publisher","first-page":"E10988","DOI":"10.1073\/pnas.1808790115","volume":"115","author":"D Bausch-Fluck","year":"2018","unstructured":"Bausch-Fluck D, Goldmann U, Muller S, van Oostrum M, Muller M, Schubert OT, et al. The in silico human surfaceome. Proc Natl Acad Sci U S A. 2018;115(46):E10988\u201397.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"1503_CR27","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1073\/pnas.1521251113","volume":"113","author":"J Town","year":"2016","unstructured":"Town J, Pais H, Harrison S, Stead LF, Bataille C, Bunjobpol W, et al. Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target. Proc Natl Acad Sci U S A. 2016;113(13):3603\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1503_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/976816","volume":"2013","author":"JP da Cunha","year":"2013","unstructured":"da Cunha JP, Galante PA, de Souza JE, Pieprzyk M, Carraro DM, Old LJ, et al. The human cell surfaceome of breast tumors. Biomed Res Int. 2013;2013: 976816.","journal-title":"Biomed Res Int"},{"issue":"2","key":"1503_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.imlet.2010.09.016","volume":"134","author":"MC Diaz-Ramos","year":"2011","unstructured":"Diaz-Ramos MC, Engel P, Bastos R. Towards a comprehensive human cell-surface immunome database. Immunol Lett. 2011;134(2):183\u20137.","journal-title":"Immunol Lett"},{"issue":"8046","key":"1503_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41586-024-08244-9","volume":"637","author":"THH Coorens","year":"2025","unstructured":"Coorens THH, Guillaumet-Adkins A, Kovner R, Linn RL, Roberts VHJ, Sule A, et al. The human and non-human primate developmental GTEx projects. Nature. 2025;637(8046):557\u201364.","journal-title":"Nature"},{"issue":"51","key":"1503_CR31","doi-asserted-by":"publisher","first-page":"E5593","DOI":"10.1073\/pnas.1419161111","volume":"111","author":"S Shen","year":"2014","unstructured":"Shen S, Park JW, Lu ZX, Lin L, Henry MD, Wu YN, et al. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc Natl Acad Sci U S A. 2014;111(51):E5593\u2013601.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"313","key":"1503_CR32","doi-asserted-by":"publisher","first-page":"313ra178","DOI":"10.1126\/scitranslmed.aad2722","volume":"7","author":"M Gustafsson","year":"2015","unstructured":"Gustafsson M, Gawel DR, Alfredsson L, Baranzini S, Bjorkander J, Blomgran R, et al. A validated gene regulatory network and GWAS identifies early regulators of T cell-associated diseases. Sci Transl Med. 2015;7(313):313ra178.","journal-title":"Sci Transl Med."},{"issue":"7","key":"1503_CR33","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1101\/gr.276042.121","volume":"32","author":"A Mikulasova","year":"2022","unstructured":"Mikulasova A, Kent D, Trevisan-Herraz M, Karataraki N, Fung KTM, Ashby C, et al. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome Res. 2022;32(7):1343\u201354.","journal-title":"Genome Res"},{"issue":"4","key":"1503_CR34","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3324\/haematol.2010.033456","volume":"96","author":"J Moreaux","year":"2011","unstructured":"Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011;96(4):574\u201382.","journal-title":"Haematologica"},{"issue":"1","key":"1503_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41408-023-00783-0","volume":"13","author":"E Liu","year":"2023","unstructured":"Liu E, Becker N, Sudha P, Dong C, Liu Y, Keats J, et al. Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway. Blood Cancer J. 2023;13(1):16.","journal-title":"Blood Cancer J"},{"issue":"16","key":"1503_CR36","first-page":"2471","volume":"139","author":"GSF Anderson","year":"2022","unstructured":"Anderson GSF, Ballester-Beltran J, Giotopoulos G, Guerrero JA, Surget S, Williamson JC, et al. Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. Blood, The Journal of the American Society of Hematology. 2022;139(16):2471\u201382.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"2","key":"1503_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2141.2011.08941.x","volume":"156","author":"N Hosen","year":"2012","unstructured":"Hosen N, Ichihara H, Mugitani A, Aoyama Y, Fukuda Y, Kishida S, et al. CD48 as a novel molecular target for antibody therapy in multiple myeloma. Br J Haematol. 2012;156(2):213\u201324.","journal-title":"Br J Haematol"},{"issue":"1","key":"1503_CR38","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","volume":"13","author":"ID Ferguson","year":"2022","unstructured":"Ferguson ID, Patino-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, et al. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun. 2022;13(1):4121.","journal-title":"Nat Commun"},{"issue":"3","key":"1503_CR39","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11523-020-00729-7","volume":"15","author":"S Ding","year":"2020","unstructured":"Ding S, Mao X, Cao Y, Wang N, Xu H, Zhou J. Targeting CD79b for chimeric antigen receptor T-cell therapy of B-cell lymphomas. Target Oncol. 2020;15(3):365\u201375.","journal-title":"Target Oncol"},{"issue":"1","key":"1503_CR40","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s41467-018-04313-6","volume":"9","author":"JM Hsu","year":"2018","unstructured":"Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9(1):1908.","journal-title":"Nat Commun"},{"issue":"12","key":"1503_CR41","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","volume":"20","author":"MT Drayson","year":"2019","unstructured":"Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019;20(12):1760\u201372.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1503_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107\u201313.","journal-title":"Haematologica"},{"issue":"4","key":"1503_CR43","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.2020008221","volume":"138","author":"T Sauer","year":"2021","unstructured":"Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021;138(4):318\u201330.","journal-title":"Blood"},{"key":"1503_CR44","doi-asserted-by":"publisher","unstructured":"Kasap C, Izgutdina A, Patino-Escobar B, Kang AS, Chilakapati N, Akagi N, et al. Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2024025536.","DOI":"10.1182\/blood.2024025536"},{"issue":"1","key":"1503_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/neuonc\/nox116","volume":"20","author":"L Jin","year":"2018","unstructured":"Jin L, Ge H, Long Y, Yang C, Chang YE, Mu L, et al. CD70, a novel target of CAR T-cell therapy for gliomas. Neuro Oncol. 2018;20(1):55\u201365.","journal-title":"Neuro Oncol"},{"issue":"5","key":"1503_CR46","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","volume":"132","author":"SR Targan","year":"2007","unstructured":"Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn\u2019s disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672\u201383.","journal-title":"Gastroenterology"},{"issue":"12","key":"1503_CR47","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49(12):1779\u201384.","journal-title":"Nat Genet"},{"issue":"6","key":"1503_CR48","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020\u20138.","journal-title":"Blood"},{"key":"1503_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652924","volume":"12","author":"Z Guo","year":"2021","unstructured":"Guo Z, Zhang Y, Fu M, Zhao L, Wang Z, Xu Z, et al. The transferrin receptor-directed CAR for the therapy of hematologic malignancies. Front Immunol. 2021;12: 652924.","journal-title":"Front Immunol"},{"issue":"8","key":"1503_CR50","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41375-024-02247-1","volume":"38","author":"IG Walker","year":"2024","unstructured":"Walker IG, Roy JP, Anderson GSF, Guerrero Lopez J, Chapman MA. Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach. Leukemia. 2024;38(8):1848\u201352.","journal-title":"Leukemia"},{"issue":"6","key":"1503_CR51","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020\u20138.","journal-title":"Blood"},{"key":"1503_CR52","doi-asserted-by":"crossref","unstructured":"Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, et al. The activated conformation of integrin beta7 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med. 2017;23:1436\u201343.","DOI":"10.1038\/nm.4431"},{"issue":"12","key":"1503_CR53","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1182\/bloodadvances.2022008559","volume":"7","author":"I Leung","year":"2023","unstructured":"Leung I, Templeton ML, Lo Y, Rajan A, Stull SM, Garrison SM, et al. Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function. Blood Adv. 2023;7(12):2718\u201330.","journal-title":"Blood Adv"},{"issue":"12","key":"1503_CR54","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1089\/hum.2017.126","volume":"28","author":"A Martyniszyn","year":"2017","unstructured":"Martyniszyn A, Krahl AC, Andre MC, Hombach AA, Abken H. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies. Hum Gene Ther. 2017;28(12):1147\u201357.","journal-title":"Hum Gene Ther"},{"issue":"10","key":"1503_CR55","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","volume":"26","author":"S John","year":"2018","unstructured":"John S, Chen H, Deng M, Gui X, Wu G, Chen W, et al. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol Ther. 2018;26(10):2487\u201395.","journal-title":"Mol Ther"},{"issue":"48","key":"1503_CR56","doi-asserted-by":"publisher","first-page":"eadg9721","DOI":"10.1126\/sciadv.adg9721","volume":"9","author":"D Li","year":"2023","unstructured":"Li D, Guo X, Yang K, Yang Y, Zhou W, Huang Y, et al. EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Sci Adv. 2023;9(48):eadg9721.","journal-title":"Sci Adv."},{"key":"1503_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.642528","volume":"12","author":"S Lin","year":"2021","unstructured":"Lin S, Cheng L, Ye W, Li S, Zheng D, Qin L, et al. Chimeric CTLA4-CD28-CD3z T cells potentiate antitumor activity against CD80\/CD86-positive B cell malignancies. Front Immunol. 2021;12: 642528.","journal-title":"Front Immunol"},{"issue":"6","key":"1503_CR58","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1172\/JCI133215","volume":"130","author":"S Guedan","year":"2020","unstructured":"Guedan S, Madar A, Casado-Medrano V, Shaw C, Wing A, Liu F, et al. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. J Clin Invest. 2020;130(6):3087\u201397.","journal-title":"J Clin Invest"},{"key":"1503_CR59","doi-asserted-by":"publisher","unstructured":"Fishilevich S, Nudel R, Rappaport N, Hadar R, Plaschkes I, Iny Stein T, et al. GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford). 2017. https:\/\/doi.org\/10.1093\/database\/bax028.","DOI":"10.1093\/database\/bax028"},{"issue":"1","key":"1503_CR60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s10020-023-00682-x","volume":"29","author":"K Edwards","year":"2023","unstructured":"Edwards K, Lydyard PM, Kulikova N, Tsertsvadze T, Volpi EV, Chiorazzi N, et al. The role of CD180 in hematological malignancies and inflammatory disorders. Mol Med. 2023;29(1):97.","journal-title":"Mol Med"},{"issue":"2","key":"1503_CR61","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1535-6108(04)00019-4","volume":"5","author":"EM Hurt","year":"2004","unstructured":"Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5(2):191\u20139.","journal-title":"Cancer Cell"},{"issue":"20","key":"1503_CR62","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1038\/sj.onc.1207418","volume":"23","author":"M Hashimoto","year":"2004","unstructured":"Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, Yuasa N, et al. Expression of CD109 in human cancer. Oncogene. 2004;23(20):3716\u201320.","journal-title":"Oncogene"},{"issue":"1","key":"1503_CR63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159\u201370.","journal-title":"Leukemia"},{"issue":"3","key":"1503_CR64","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/sj.leu.2404524","volume":"21","author":"WJ Chng","year":"2007","unstructured":"Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E, et al. Clinical significance of TP53 mutation in myeloma. Leukemia. 2007;21(3):582\u20134.","journal-title":"Leukemia"},{"issue":"2","key":"1503_CR65","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/bjh.17670","volume":"195","author":"EM Boyle","year":"2021","unstructured":"Boyle EM, Rosenthal A, Wang Y, Farmer P, Rutherford M, Ashby C, et al. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. Br J Haematol. 2021;195(2):283\u20136.","journal-title":"Br J Haematol"},{"key":"1503_CR66","doi-asserted-by":"publisher","unstructured":"Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485). https:\/\/doi.org\/10.1126\/scitranslmed.aau7746.","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"1503_CR67","first-page":"1 30","volume":"54","author":"G Stelzer","year":"2016","unstructured":"Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 2016;54:1 30-1 3.","journal-title":"Curr Protoc Bioinformatics."},{"issue":"10","key":"1503_CR68","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1002\/cncr.11072","volume":"97","author":"VM Lauta","year":"2003","unstructured":"Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer. 2003;97(10):2440\u201352.","journal-title":"Cancer"},{"key":"1503_CR69","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.canlet.2018.10.028","volume":"442","author":"JM Zhang","year":"2019","unstructured":"Zhang JM, Wang CC, Zhang GC, Jiang Q, Yang SM, Fu HX, et al. ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. Cancer Lett. 2019;442:193\u2013201.","journal-title":"Cancer Lett"},{"issue":"8","key":"1503_CR70","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","volume":"5","author":"E Ramberger","year":"2024","unstructured":"Ramberger E, Sapozhnikova V, Ng YLD, Dolnik A, Ziehm M, Popp O, et al. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Nat Cancer. 2024;5(8):1267\u201384.","journal-title":"Nat Cancer"},{"issue":"12","key":"1503_CR71","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41577-018-0068-5","volume":"18","author":"BN Lambrecht","year":"2018","unstructured":"Lambrecht BN, Vanderkerken M, Hammad H. The emerging role of ADAM metalloproteinases in immunity. Nat Rev Immunol. 2018;18(12):745\u201358.","journal-title":"Nat Rev Immunol"},{"issue":"15","key":"1503_CR72","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1182\/blood.2019003179","volume":"135","author":"E Tissino","year":"2020","unstructured":"Tissino E, Pozzo F, Benedetti D, Caldana C, Bittolo T, Rossi FM, et al. CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. Blood. 2020;135(15):1244\u201354.","journal-title":"Blood"},{"issue":"9","key":"1503_CR73","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.4049\/jimmunol.174.9.5612","volume":"174","author":"M Zhu","year":"2005","unstructured":"Zhu M, Granillo O, Wen R, Yang K, Dai X, Wang D, et al. Negative regulation of lymphocyte activation by the adaptor protein LAX. J Immunol. 2005;174(9):5612\u20139.","journal-title":"J Immunol"},{"issue":"8","key":"1503_CR74","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1128\/MCB.01331-13","volume":"34","author":"MC Banton","year":"2014","unstructured":"Banton MC, Inder KL, Valk E, Rudd CE, Schneider H. Rab8 binding to immune cell-specific adaptor LAX facilitates formation of trans-Golgi network-proximal CTLA-4 vesicles for surface expression. Mol Cell Biol. 2014;34(8):1486\u201399.","journal-title":"Mol Cell Biol"},{"key":"1503_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626616","volume":"12","author":"J Ma","year":"2021","unstructured":"Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, et al. Bispecific Antibodies: From Research to Clinical Application. Front Immunol. 2021;12: 626616.","journal-title":"Front Immunol"},{"key":"1503_CR76","unstructured":"Brian Walker. Identification of novel immunotherapy targets in myeloma. dbGAP. 2025;phs003772.v1.p1. https:\/\/www.ncbi.nlm.nih.gov\/projects\/gap\/cgi-bin\/study.cgi?study_id=phs003772.v1.p1."},{"key":"1503_CR77","unstructured":"Keats J. Relating clinical outcomes in multiple myeloma to personal assessment of genetic profile. dbGAP. 2019;phs000748.v7.p4. https:\/\/www.ncbi.nlm.nih.gov\/projects\/gap\/cgi-bin\/study.cgi?study_id=phs000748.v7.p4."},{"key":"1503_CR78","unstructured":"Travis Johnson BW. Identification of high-risk PHF19 expressing cells in myeloma single-cell multiomics. dbGAP. 2024;phs003220.v2.p1. https:\/\/www.ncbi.nlm.nih.gov\/projects\/gap\/cgi-bin\/study.cgi?study_id=phs003220.v2.p1."},{"key":"1503_CR79","unstructured":"Gawel D. A validated gene regulatory network and GWAS identifies early regulators of T-cell associated diseases (ChIP-Seq). Gene Expression Omnibus. 2015;GSE72266. https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE72266."},{"key":"1503_CR80","unstructured":"Chng WJ. Aberrant hyperediting of myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Gene Expression Omnibus. 2018;GSE110486. https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE110486."},{"key":"1503_CR81","unstructured":"Meydan C. Long non-coding RNAs discriminate the stages and gene regulatory states of the human humoral immune response (RNA-Seq). Gene Expression Omnibus. 2019;GSE114816. https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE114816."},{"key":"1503_CR82","unstructured":"Walker ELaB. Novel Immunotherapeutic Targets in MM. Zenodo. 2025.https:\/\/zenodo.org\/records\/15708580."}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01503-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-025-01503-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01503-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T12:41:41Z","timestamp":1757248901000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-025-01503-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1503"],"URL":"https:\/\/doi.org\/10.1186\/s13073-025-01503-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.01.29.635544","asserted-by":"object"}]},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ninety-four (44 newly diagnosed and 50 relapsed) samples in IU dataset were collected as part of the Indiana Myeloma Registry, a prospective, non-interventional, observational study (NCT03616483) where patients gave informed consent for use of samples for research purposes. The study was approved by Indiana University IRB (#1804208190). All research conformed with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"V.S.C., H.H., F.Z. and M.N. are employed by and hold stock in Genentech Inc. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}